07.01.02
New Developments
At Acatris
Minneapolis, MN-based Acatris USA Inc., along with Acatris Holding B.V., Giessen, The Netherlands, is supplying its soy supplement ingredient—SoyLife®—to be the focus of an upcoming women’s health study conducted by researchers at the Baylor College of Medicine, Houston, TX. This $4.5 million study will examine the potential health benefits of soy isoflavone supplementation over a two year period in reducing bone loss in postmenopausal women.
In other developments, Acatris and Schouten Products have opened a new factory for the production of SoyLife® (natural soy germ isoflavone concentrates) in Poederooijen, The Netherlands. The new factory expands the existing facilities and guarantees the quality and continuity of the supply of Identity Preserved, non-GMO SoyLife®.
At Acatris
Minneapolis, MN-based Acatris USA Inc., along with Acatris Holding B.V., Giessen, The Netherlands, is supplying its soy supplement ingredient—SoyLife®—to be the focus of an upcoming women’s health study conducted by researchers at the Baylor College of Medicine, Houston, TX. This $4.5 million study will examine the potential health benefits of soy isoflavone supplementation over a two year period in reducing bone loss in postmenopausal women.
In other developments, Acatris and Schouten Products have opened a new factory for the production of SoyLife® (natural soy germ isoflavone concentrates) in Poederooijen, The Netherlands. The new factory expands the existing facilities and guarantees the quality and continuity of the supply of Identity Preserved, non-GMO SoyLife®.